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expression by Luminex and ELISPOT assays, and cytotox-
icity by myeloma cell counts. Elotuzumab activated NK 
cells and promoted myeloma cell death in PBL/myeloma 
cell co-cultures. The combination of elotuzumab plus lena-
lidomide demonstrated superior anti-myeloma activity on 
established MM xenografts in vivo and in PBL/myeloma 
cell co-cultures in vitro than either agent alone. The com-
bination enhanced myeloma cell killing by modulating NK 
cell function that coincided with the upregulation of adhe-
sion and activation markers, including interleukin (IL)-2Rα 
expression, IL-2 production by CD3+CD56+ lymphocytes, 
and tumor necrosis factor (TNF)-α production. In co-cul-
ture assays, TNF-α directly increased NK cell activation 
and myeloma cell death with elotuzumab or elotuzumab 
plus lenalidomide, and neutralizing TNF-α decreased NK 
cell activation and myeloma cell death with elotuzumab. 
These results demonstrate that elotuzumab activates NK 
cells and induces myeloma cell death via NK cell-mediated 
ADCC, which is further enhanced when combined with 
lenalidomide.
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Abbreviations
ADCC  Antibody-dependent cellular cytotoxicity
DMSO  Dimethylsulfoxide
GFP  Green fluorescent protein
IFN-γ  Interferon-γ
mAb  Monoclonal antibody
MM  Multiple myeloma
NK  Natural killer
IL  Interleukin
PBLs  Peripheral blood lymphocytes
Abstract Elotuzumab is a humanized monoclonal 
antibody specific for signaling lymphocytic activation 
molecule-F7 (SLAMF7, also known as CS1, CD319, or 
CRACC) that enhances natural killer (NK) cell-medi-
ated antibody-dependent cellular cytotoxicity (ADCC) of 
SLAMF7-expressing myeloma cells. This study explored 
the mechanisms underlying enhanced myeloma cell kill-
ing with elotuzumab as a single agent and in combina-
tion with lenalidomide, to support ongoing phase III trials 
in patients with relapsed/refractory or newly-diagnosed 
multiple myeloma (MM). An in vitro peripheral blood 
lymphocyte (PBL)/myeloma cell co-culture model was 
developed to evaluate the combination of elotuzumab and 
lenalidomide. Expression of activation markers and adhe-
sion receptors was evaluated by flow cytometry, cytokine 
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PBMCs  Peripheral blood mononuclear cells
PBS  Phosphate-buffered saline
SLAM  Signaling lymphocytic activation molecule
TNF-α  Tumor necrosis factor-α
VEGF  Vascular endothelial growth factor
Introduction
Multiple myeloma (MM) is a disease of malignant plasma 
cells in the bone marrow characterized by anemia, lytic 
bone lesions, and elevated M protein in blood or urine and 
is associated with renal dysfunction [1]. MM represents 
1 % of all neoplasms and about 13 % of hematological can-
cers in the USA. Recent advances in treatment options have 
improved overall survival in patients with MM [2]. Lena-
lidomide, approved in combination with dexamethasone 
for the treatment of MM, exerts anti-myeloma activity by 
multiple mechanisms, including enhancing immune func-
tion [3–12]. Although progress has been made in treating 
MM, most of these patients will eventually become refrac-
tory to current treatment and subsequently relapse. Thus, 
the development of novel targeted therapies and optimal 
combination strategies is needed to fill a significant unmet 
medical need in the treatment of patients with refractory/
relapsed MM.
Monoclonal antibodies (mAbs) targeting a variety of 
myeloma cell surface antigens are currently under clini-
cal investigation. The targets of these mAbs include CD38 
[13], CD56 [14], CD138 [15], CD200 [16], HM1.24 [17], 
and RankL [18]. Other targets of mAbs include antagonists 
of soluble molecules that support myeloma growth such 
as interleukin (IL)-6 [19] and vascular endothelial growth 
factor (VEGF) [20]. These mAbs may exert anti-mye-
loma activity through a variety of mechanisms, including 
direct induction of cytotoxicity via apoptosis, complement 
dependent cytotoxicity, antibody-dependent cellular cyto-
toxicity (ADCC), antibody-dependent cellular phagocyto-
sis, and as antibody drug conjugates to deliver cytotoxic 
payloads.
SLAMF7, a member of the immunoglobulin (Ig) gene 
superfamily, is highly expressed on the surface of MM cells 
with restricted expression on specific lymphocytes includ-
ing resting natural killer (NK) cells, NKT cells, CD8+T 
cells, activated monocytes, and activated B cells [21]. 
Given its highly and almost universal expression on MM 
cells [22], SLAMF7 was identified as a target of MM ther-
apy. Elotuzumab is a humanized IgG1 anti-SLAMF7 mAb 
under clinical investigation for the treatment of relapsed/
refractory newly-diagnosed MM, and high-risk smoldering 
myeloma [2, 23]. In preclinical models, elotuzumab exerts 
NK cell-mediated target cell killing via ADCC in vitro and 
has demonstrated antitumor activity in vivo in established 
myeloma xenograft models [21, 22, 24, 25]. Elotuzumab 
also promotes cytotoxicity against SLAMF7-expressing 
myeloma cells by mechanisms other than ADCC, including 
direct activation of NK cells [26].
A clinical phase I dose-escalation study in patients with 
relapsed/refractory MM demonstrated that elotuzumab had 
acceptable tolerability at doses sufficient to achieve biolog-
ically relevant serum concentrations and saturate SLAMF7 
on myeloma cells in bone marrow [27]. Recent phase II 
results in the same patient population reported encouraging 
tolerability and efficacy of elotuzumab in combination 
with lenalidomide plus low-dose dexamethasone [28]. 
Based on these results, phase III trials of elotuzumab with 
lenalidomide plus low-dose dexamethasone were initiated 
in patients with both newly-diagnosed (ELOQUENT-1; 
NCT01335399) and relapsed/refractory MM (ELO-
QUENT-2; NCT01239797).
The objective of the preclinical studies reported here 
was to provide a mechanistic understanding and strengthen 
the rationale of combining elotuzumab with lenalidomide 
for treating patients with MM. Preliminary evidence sug-
gested that pretreatment of either effector NK cells or target 
myeloma cells with lenalidomide enhanced elotuzumab-
mediated ADCC against myeloma cells [24]. Our studies 
expanded on these findings in a cell co-culture model to 
further evaluate the anti-myeloma activity of the combina-
tion of elotuzumab with lenalidomide.
Materials and methods
Cells and cell lines
An in vitro co-culture model of human peripheral blood 
lymphocytes (PBLs) and myeloma cells was developed to 
evaluate the mechanism(s) underlying the activity of the 
elotuzumab and lenalidomide combination. Blood was 
collected from healthy adult donors, and peripheral blood 
mononuclear cells (PBMCs) were isolated by Ficoll-
Paque™ PLUS (GE Healthcare) according to the manu-
facturer’s instructions. Monocytes were depleted from the 
PBMCs using CD14 microbeads (Miltenyi Biotec, Inc., 
Auburn, CA) or CD14 positive selection kit (StemCell 
Technologies), and the preparation was confirmed to be 
>90 % depleted of monocytes. PBMCs depleted of mono-
cytes (PBL-enriched) were used in the assays.
NK cells were enriched from PBMCs using EasySep® 
NK cell negative selection kit (StemCell Technologies) and 
confirmed to be >90 % pure by flow cytometry for CD56. 
Co-cultures enriched or depleted in CD56+ lymphocytes 
were used in experiments to determine IL-2 production 
and the frequency of IL-2-producing cells in treated cul-
tures (see below). The SLAMF7/CS1+ myeloma cell line 
63Cancer Immunol Immunother (2015) 64:61–73 
1 3
OPM2 was obtained from the DSMZ (German Collection 
of Microorganisms and Cell Culture). IM-9, LP-1, and 
L363 cell lines were obtained from ATCC. Lenti-green 
fluorescent protein (GFP) transfection vector (Invitrogen) 
was used to generate OPM2-, L363-, IM-9-, and LP-1-GFP 
cells following the manufacturer’s instructions.
Reagents
The generation of elotuzumab [humanized antihuman 
SLAMF7 (CS1) IgG1 mAb] and isotype control human 
IgG1 mAb MSL109 (cIgG1) was described previously 
[21]. Lenalidomide was custom synthesized; its structure 
was confirmed by nuclear magnetic resonance spectrom-
etry and the purity was determined to be 99.8 %. A vari-
ant of elotuzumab was generated with an IgG2 backbone 
and mutations in the Fc region (Elo IgG2M3) as previ-
ously described [29]. F(ab′)2 fragments of elotuzumab and 
MSL109 (cIgG1) were generated through pepsin diges-
tion from intact parental antibodies and were found to be 
completely devoid of intact IgG and free of endotoxin. 
Recombinant human IL-2 was purchased from Roche, and 
tumor necrosis factor (TNF)-α and interferon (IFN)-γ were 
purchased from R&D Systems. Elotuzumab F(ab′)2 bind-
ing to SLAMF7 was functionally confirmed by its ability 
to inhibit the binding of elotuzumab-FITC to SLAMF7 on 
myeloma cell lines by flow cytometry.
In vivo myeloma mouse xenograft model
Female ICRTac:ICR Prkdcscid mice (6–8 weeks of age) 
were obtained from Taconic Farms. After resting for 
3–4 days, mice were inoculated in the lower right flank 
with 1 × 107 OPM2 cells in RPMI-1640 (HyClone). 
Caliper measurements were done three times weekly 
for the calculation of tumor volume as described pre-
viously [24], and tumor growth was monitored for a 
period of 6 weeks. Tumor volume was calculated from 
length × width × height/2, where length is the longest side 
of the tumor in the plane of the animal’s back, width is the 
longest measurement perpendicular to the length and in the 
same plane, and height is the highest point perpendicular 
to the back of the animal. Mice with an average tumor size 
of ~100 mm3 were randomized into treatment groups of 8 
mice each. Lenalidomide in dimethylsulfoxide (DMSO) at 
50 mg/kg was administered intraperitoneally in phosphate-
buffered saline (PBS) daily for 5 days/week.
Suboptimal dosing of elotuzumab (1 mg/kg) or MSL109 
(cIgG1) (1 mg/kg) in PBS with equivalent concentration 
of DMSO to that of lenalidomide (50 mg/kg) was admin-
istered intraperitoneally twice weekly. Experiments were 
terminated once tumors reached a size of >2,000 mm3. 
Statistical differences between the treatment groups were 
determined by t test using SAS statistical software. Mean 
tumor volumes between groups were considered signifi-
cantly different if P ≤ 0.05. All studies were approved 
by the Institutional Animal Care and Use Committee in 
accordance with the “Guide for the Care and Use of Labo-
ratory Animals” (National Research Council).
Immunohistochemistry of xenograft tissues
Xenograft tumors were harvested 24 h posttreatment. Goat 
anti-NKp46 (R&D Systems) goat antibody and Alexa 
Fluor® 594 donkey anti-goat IgG (Invitrogen) secondary 
antibodies were used to detect mouse NK cells in OCT-
embedded frozen xenograft sections. Slides were mounted 
in DAPI mounting medium (Vector Labs), and images 
taken on a fluorescent microscope (Zeiss Axioskop-2). 
Three fields per tumor at 400× magnification were used for 
image analysis by Image-Pro Plus software.
PBL/myeloma co-culture assays
PBLs (2 × 106/mL) from healthy adult donors were co-cul-
tured with lenti-GFP OPM2 target cells (0.2 × 106/mL) at 
a 10:1 ratio (1 mL/well) in 24-well, flat bottom tissue cul-
ture plates. Antibodies (elotuzumab or cIgG1 MSL109) were 
used at 20 μg/mL. Lenalidomide was dissolved in DMSO 
and added to wells at 1 μM. Lenalidomide 10 μM was 
added to co-cultures used for enzyme-linked immunosorbent 
spot (ELISPOT) assays. Equimolar concentrations of DMSO 
were used as a control. Upon addition of all the reagents and 
cells, the tissue culture plates were incubated for 24–72 h at 
37 °C/5 % CO2. For blocking studies, neutralizing mouse 
mAb to human IL-2 (clone 5334; R&D Systems), blocking 
humanized mAb to CD25 (daclizumab), neutralizing human-
ized mAb to IFN-γ (HuZAF), neutralizing fully human mAb 
to TNF-α (D2E7), and blocking mouse mAbs to lympho-
cyte function-associated antigen (LFA)-1 (clone H155-78; 
BioLegend) were added at 20 μg/mL. Harvested cells were 
treated with 2 μM EDTA for 30 min at 37 °C, then pipet-
ted thoroughly, collected into 1.5-mL centrifuge tubes, and 
spun at 2,000 rpm for 10 min. The supernatants were col-
lected and stored at −80 °C until use for cytokine determina-
tion in Luminex assays, which were performed for measur-
ing cytokines and growth factors (IL-2, IFN-γ and TNF-α, 
IL-6, IL-8, IL-15, IL-10, VEGF, and epidermal growth fac-
tor) using Millipore MAP human cytokine kits (Millipore). 
The cell pellets were suspended in 200 μL FACS buffer, and 
a 50 μL sample was dispensed for immunostaining.
Flow cytometry
To assess the activation of CD3−CD16+CD56+ NK cells, 
cells were stained with CD16 PE (clone 3G8 or B73.1), 
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CD56 PE (clone MY31), and CD3 APC H7 (clone SK7) 
to identify NK cells, and CD54 APC (clone HA58) and 
CD25 PEcy7 (clone MA-251) (all from BD Biosciences, 
San Diego, CA) to assess activation status. Dead cells were 
gated out using propidium iodide. Lenti-GFP-OPM2 cells 
were used in the assay to facilitate the gating of myeloma 
cells from the PBL. To quantify the number of myeloma 
cells, 30 μL of FITC-QuantiBRITE® beads (Polysciences, 
Inc.) containing approximately 30,000 beads was added to 
each tube at the time of staining. Data were acquired on 
FACSCanto™ (Becton–Dickinson), and acquisition was 
stopped when 5,000 bead events were acquired. Data were 
analyzed using FACS DIVA software.
Cell growth assays
OPM2 cells at 500 cells/well were seeded in 96-well flat 
bottom tissue culture plates. Titrated doses of soluble or 
immobilized control IgG1 or elotuzumab mAb were added 
to the wells. Cell viability was measured by exposing cells 
to Alamar Blue for 2 h at 37 °C. Fluorescence was emit-
ted for excitation at 544 nm, and emission was measured at 
590 nm. Relative viability was calculated by dividing the 
fluorescence of elotuzumab-treated or control IgG-treated 
samples with that of untreated cells. Assay results repre-
sent the reading from triplicate wells. Each assay was done 
twice, with one representative assay shown.
IL-2 specific ELISPOT assay
To determine the frequency of IL-2-secreting cells, co-cul-
tures were set up for 48 h. Cells were collected, and resid-
ual target cells were removed by positive CD138 micro-
bead selection (Miltenyi Biotec, Inc.). PBMC subtraction 
assays of T cells or NK cells were performed using positive 
magnetic bead selection of CD3 or CD56 (StemCell Tech-
nologies, Vancouver, Canada). Depletion of cell popula-
tions was confirmed by flow cytometry. FACS sorting of 
CD56+CD3+ T cells was achieved by labeling the treated 
PBMC cultures with CD56 PE and CD3 APC antibodies. 
Ninety-six well Immobilon-P high protein binding plates 
(Millipore, Hayward, CA) were coated with 5 μg/mL cap-
ture antihuman IL-2 Ab (BD Biosciences, San Diego, CA) 
in PBS, incubated overnight at 4 °C, and blocked with 
medium containing 10 % FBS for 2 h at room temperature. 
Total PBMCs were re-suspended in complete medium and 
plated at 5 × 105 cells per well in triplicate wells and incu-
bated for 24 h at 37 °C. Following incubation, cells were 
removed by two distilled H20 washes followed by three 
washes with 0.05 % Tween-PBS. Biotinylated antihuman 
IL-2 detection Ab (BD Biosciences) was added (2 μg/mL) 
and then incubated for 2 h at room temperature. After three 
washes with 0.05 % Tween-PBS, plates were incubated 
with 100 μL of a 1:1,000 dilution of peroxidase-conjugated 
streptavidin (Jackson ImmunoResearch, West Grove, PA) 
for 1 h at room temperature. Plates were washed four times 
with 0.05 % Tween-PBS and developed in 100 μL AEC 
substrate (BD Biosciences) for 30 min, and then stopped 
with two distilled H20 washes (200 μL). Plates were dried 
overnight, and spots were recorded and quantified by an 
Immunospot® plate reader (CTL, Shaker Heights, OH).
Results
Elotuzumab enhanced antitumor activity in combination 
with lenalidomide and promoted NK cell recruitment 
to myeloma xenografts
The combinatorial effects of elotuzumab with lenalidomide 
in an in vivo setting were investigated in subcutaneous 
OPM2 xenografts implanted in severe combined immu-
nodeficient (SCID) mice. Inhibition of tumor growth was 
seen with lenalidomide (50 mg/kg/day at 5 days/week) or 
a suboptimal dose of elotuzumab (1 mg/kg twice/week for 
3 weeks), but established tumors were not fully eradicated. 
Elotuzumab alone had considerable antitumor activity as 
compared with cIgG1 control and was similar to lenalido-
mide alone (Fig. 1a). Elotuzumab plus lenalidomide dem-
onstrated enhanced anti-myeloma activity and suppressed 
tumor growth to a much greater extent than either single 
agent.
To test whether the enhanced anti-myeloma activity 
of the combination of elotuzumab and lenalidomide was 
the result of increased immune cell infiltration into the 
xenografts, immunohistochemistry was performed on 
established OPM2 xenografts to identify the presence of 
NKp46+ NK cells and F4/80+ monocyte infiltrates from 
mice treated with cIgG1, elotuzumab, cIgG1 plus lena-
lidomide, or elotuzumab plus lenalidomide. Compared 
with cIgG1, elotuzumab treatment recruited NKp46+ NK 
cells into xenograft tumors, whereas lenalidomide alone 
did not (Fig. 1b). However, the frequency of NKp46+ 
cell infiltrates was not significantly greater in the OPM2 
xenografts of mice treated with elotuzumab plus lenalid-
omide compared to mice treated with elotuzumab alone 
when counted per visual field (Fig. 1c). No difference 
in monocyte infiltrates was observed between any of the 
treatment groups (data not shown). Furthermore, a vari-
ant of elotuzumab with an IgG2 backbone and Fc region 
mutations (Elo IgG2M3), which abrogated ADCC activ-
ity in vitro, did not inhibit tumor xenograft growth and 
failed to recruit NK cells into the xenografts (data not 
shown).
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Elotuzumab plus lenalidomide enhanced myeloma cell 
killing in co-cultures compared to either agent alone
Conventional ADCC assays performed with NK cells or 
myeloma cells preincubated with lenalidomide were unable 
to define the combinatorial activity of elotuzumab with lena-
lidomide in an in vitro setting (data not shown). In order to 
analyze potential immune mechanism(s) of elotuzumab com-
bined with lenalidomide, a human PBL/myeloma co-culture 
model was developed (see Materials and methods). Using this 
model, the effects of elotuzumab and lenalidomide (alone or 
in combination) could be simultaneously tested on NK cell 
activation, cytokine production, and myeloma cell killing 
(determined by myeloma cell counts). Co-cultures were incu-
bated for 48 or 72 h, a time substantially longer than a typi-
cal 4-h ADCC assay, which enabled the immunomodulatory 
effects of lenalidomide to have maximal impact.
Elotuzumab alone induced significant myeloma cell kill-
ing as compared with cIgG1 (Fig. 2a), but the combination 
of elotuzumab plus lenalidomide significantly decreased 
the number of OPM2 cells compared with elotuzumab or 
lenalidomide treatment alone (Fig. 2a). Concomitant with 
the decrease in OPM2 cells observed in the co-cultures, the 
combination significantly increased the activation of NK 
cells as determined by an increase in expression of CD25 
(IL-2 receptor α [IL-2 Rα]) (Fig. 2b) and CD54 (ICAM-
1, Fig. 2c). Lenalidomide alone had little effect on CD25 
expression on NK cells, although it significantly increased 
CD54 expression. Relative to lenalidomide, elotuzumab 
alone slightly increased CD25 expression in NK cells, but 
was comparable in its propensity to increase CD54 expres-
sion in NK and OPM2 cells (Fig. 2c, d). Similar results were 
obtained using other SLAMF7-positive myeloma cells, 
including IM-9, LP-1, and L363 cells (data not shown).
Fig. 1  Elotuzumab in combination with lenalidomide enhanced anti-
myeloma activity in vivo. a Mice with established OPM2 xenograft 
tumors (average of ~100 mm2) were randomized into groups (n = 8/
group) and treated with control IgG1 (cIgG1), elotuzumab (Elo), 
cIgG1 plus lenalidomide (cIgG1 + Len), or Elo + Len. Inverted 
empty triangles depict lenalidomide dosing; inverted filled triangles 
depict Elo dosing. Representative data from one of four independent 
studies are shown. cIgG1 versus Elo, Len, or Elo + Len, P < 0.05; 
Len or Elo versus Elo + Len, P < 0.05; Elo versus Len P > 0.05. b 
Immunofluorescence staining (magnification 400×) of frozen sec-
tions of OPM2 xenograft tumors for NKp46 cell infiltration (red) on 
day 1 post-dosing of cIgG1, Elo, cIgG1 + Len, or Elo + Len. Infil-
tration of NKp46 cells in OPM2 xenograft tumors was observed in 
mice treated with Elo or the Elo + Len combination. c Image anal-
ysis of NKp46 cell infiltration in OPM2 xenografts on day 1 post-
dosing. Total amount of NKp46+ cell infiltrate (in arbitrary units) 
of each tumor was measured by image analysis software (Image-Pro 
Plus). Each symbol represents one field of image. Three 400× fields 
were randomly chosen from each tumor xenograft for image analysis. 
cIgG1 versus Elo, P < 0.01; Elo versus Elo + Len, P > 0.05
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Combinatorial activity was dependent on elotuzumab Fc 
and NK cell LFA-1
To determine whether NK cell LFA-1 interactions with its 
ligands are functionally relevant for OPM2 killing, block-
ing studies with a mAb against CD18 (LFA-1β chain) 
were performed. Addition of anti-CD18 mAb significantly 
decreased myeloma cell killing in elotuzumab and elo-
tuzumab plus lenalidomide-treated cultures as compared 
with control. The addition of an anti-CD54 mAb to elotu-
zumab and elotuzumab plus lenalidomide-treated cultures 
also significantly decreased myeloma cell killing, although 
to a lesser extent than that obtained by blocking with anti-
CD18 mAb (Fig. 3a). We also examined whether addition 
of anti-CD18 mAb was accompanied by inhibition of NK 
cell activation. The addition of a mAb against CD18 signif-
icantly inhibited NK cell activation in elotuzumab and elo-
tuzumab plus lenalidomide-treated cultures (Fig. 3b). The 
full combinatorial activity of elotuzumab plus lenalidomide 
in the co-cultures was therefore dependent on LFA-1 bind-
ing to one or more of its ligands.
NK cells express two potential binding sites for elotu-
zumab: SLAMF7 and CD16 (FcγRIIIa). To determine 
whether elotuzumab-mediated NK cell activation and mye-
loma cell killing resulted from ligation of SLAMF7 and/
or CD16, we tested the effects of Fc deficient elotuzumab 
F(ab′)2 on NK cell activation and myeloma cell killing in 
the co-cultures. Soluble elotuzumab F(ab′)2 alone or in 
combination with lenalidomide failed to mediate myeloma 
cell killing (Fig. 3c) and induce certain NK cell activation 
markers (CD25 and CD54 expression) in the co-culture 
model examined (Fig. 3d). Elotuzumab has been reported 
to also potentially work through an additional mechanism 
by bridging SLAMF7 molecules between NK cells and 
target cells [22, 26]. However, in this specific co-culture 
system, any bridging of SLAMF7 between effector and 
Fig. 2  Elotuzumab plus lenalidomide combination enhanced mye-
loma cell killing and NK cell activation in PBL/myeloma cell co-
cultures in vitro. Elotuzumab (Elo) plus lenalidomide (Len) signifi-
cantly decreased myeloma cell (OPM2) counts compared with Elo 
(P < 0.01) or Len (P = 0.01) (n = 5) (a). Effect of Elo ± Len on 
CD25 (b) and ICAM-1 (c, d) expression on NK and OPM2 cells 
(n = 4–8). Elo + Len significantly enhanced both IL-2 Rα (P < 0.01 
vs. Elo; P < 0.01 vs. Len) and ICAM-1 (P < 0.01 vs. Elo; P < 0.01 
vs. Len) expression on NK and OPM2 cells more than either agent 
alone. Elo significantly induced IL-2 Rα (CD25) (P < 0.03) and 
ICAM-1 (CD54) (P < 0.01) expression on NK cells more than cIgG1-
treated cultures. However, Len had little effect on IL-2 Rα expression 
(P > 0.05), but significantly increased ICAM-1 (P < 0.01) expression 
on NK cells. Neither agent alone had an effect on CD54 expression in 
OPM2 cells compared with cIgG1
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target cells was not sufficient to induce NK cell activation 
and myeloma cell killing. Under the conditions tested, the 
activity of elotuzumab plus lenalidomide combination was, 
therefore, dependent on the engagement of elotuzumab Fc 
to CD16.
Inflammatory cytokine TNF-α, but not IFN-γ, contributed 
to combination activity
We investigated whether the increased activation of NK 
cells observed in the PBL/myeloma co-cultures treated 
with elotuzumab or elotuzumab plus lenalidomide was 
associated with changes in cytokine production. Elotu-
zumab alone induced low levels of IFN-γ and TNF-α secre-
tion. Elotuzumab plus lenalidomide significantly enhanced 
soluble IFN-γ and TNF-α cytokine levels as compared with 
either agent alone (Fig. 4a, b). To address whether these 
cytokines contributed to NK cell activation and myeloma 
cell killing, neutralization experiments were performed 
with blocking antibodies. Neutralization of TNF-α, but 
not IFN-γ, significantly inhibited myeloma cell killing 
(Fig. 4c) and NK cell activation (Fig. 4d, e) in elotuzumab, 
as well as elotuzumab plus lenalidomide co-cultures.
We also examined whether TNF-α or IFN-γ could exert 
anti-myeloma activity in the absence of effector cells. 
Cytotoxicity assays were performed by incubating mye-
loma cells with TNF-α and IFN-γ. TNF-α, but not IFN-
γ, exerted direct dose-dependent anti-myeloma activity 
(Fig. 4f) at doses that were in the range of soluble TNF-α 
levels (50–250 pg/mL) produced in the co-cultures. Taken 
together, these results demonstrate that elotuzumab plus 
lenalidomide increases soluble TNF-α and IFN-γ levels 
and that TNF-α contributes to increased NK cell activation 
and myeloma cell killing. Based on the results of activation 
Fig. 3  NK cell activation and myeloma killing are LFA-1 and CD16-
dependent. a Inhibition of myeloma cell killing in PBL/myeloma 
cell co-cultures in the presence of anti-CD18 mAb (n = 6). Addi-
tion of anti-CD18 (LFA-1) mAb decreased myeloma cell killing 
in elotuzumab (Elo) plus lenalidomide (Len) (P < 0.01) and Elo 
(P = 0.01)-treated co-cultures more than control IgG1-treated cul-
tures (labeled CD18/54). b Inhibition of CD25 upregulation on NK 
cells in PBL/myeloma cell co-cultures in the presence of anti-CD18 
mAb (n = 6). Addition of anti-CD18 (LFA-1) mAb decreased 
CD25 upregulation on NK cells in Elo + Len (P < 0.01)- and Elo 
(P < 0.05)-treated cultures more than cIgG1-treated cultures. c 
Requirement of Fc–FcR interaction for Elo-mediated myeloma cell 
killing (n = 4). Elo-F(ab′)2 did not mediate myeloma cell killing as 
compared to Elo alone (P > 0.05), nor did it increase myeloma cell 
inhibition by Len. d Elo-mediated CD25 upregulation on NK cells 
requires Fc–FcR interaction. Elo-F(ab′)2 did not stimulate the upreg-
ulation of CD25 as compared with Elo alone (P > 0.05) or in combi-
nation with Len
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assays with NK, PBMC-NK, PBMC-T, and PBMC-mono-
cyte cultures in the presence of elotuzumab or cIgG1, NK 
cells and monocytes but not T cells contribute to TNF-α 
production (data not shown).
Enhanced production and consumption of IL-2 in the 
presence of elotuzumab
Using PBMC/myeloma cell co-cultures enriched in CD56+ 
NK cells, we examined whether lenalidomide or the elo-
tuzumab plus lenalidomide combination induced IL-2 
production. Consistent with previous reports (4, 30, 31), 
the levels of IL-2 were higher in lenalidomide plus cIgG1-
treated cultures than those treated with cIgG1 (Fig. 5a). In 
contrast, IL-2 levels were decreased in the cultures treated 
with elotuzumab, either alone or in combination with lena-
lidomide. The reduction in IL-2 levels coincided with CD25 
expression on NK cells in elotuzumab and elotuzumab plus 
lenalidomide cultures (Fig. 2b). Based on these observa-
tions, we hypothesized that decreased IL-2 levels may 
be a result of IL-2 consumption by NK cells. To test this 
hypothesis, we performed IL-2 blocking experiments with 
anti-IL-2Rα (anti-CD25) mAb. The addition of anti-CD25 
mAb to the elotuzumab or elotuzumab plus lenalidomide 
Fig. 4  TNF-α and IFN-γ secretion induced by elotuzumab (Elo) 
in combination with lenalidomide (Len). TNF-α stimulated NK 
cell activation and myeloma cell killing. (Elo) plus (Len) enhanced 
a soluble IFN-γ (n = 8) and b TNF-α (n = 8) cytokines in the 
PBL/myeloma cell co-cultures as determined by Luminex assays. 
Elo + Len significantly enhanced soluble IFN-γ (P < 0.05 vs. Elo; 
P < 0.05 vs. Len) and TNF-α (P < 0.05 vs. Elo; P < 0.01 vs. Len) 
cytokines as compared with either agent alone. c Neutralization of 
TNF-α (n = 4), but not IFN-γ (n = 4), significantly inhibited mye-
loma cell killing (P < 0.02 for Elo + anti-TNF-α vs. Elo + cIgG1; 
P < 0.01 for Elo + Len + anti-TNF-α vs. Elo + Len + cIgG1). 
d Neutralization of TNF-α (n = 4), but not IFN-γ (n = 4), sig-
nificantly decreased CD25 expression on NK cells (P < 0.01 for 
Elo + anti-TNF-α vs. Elo + cIgG1; P < 0.05 for Elo + Len + anti-
TNF-α vs. Elo + Len + cIgG1). e Neutralization of TNF-α (n = 4) 
but not IFN-γ (n = 4) significantly affected CD54 expression on NK 
cells (P < 0.01 for Elo + anti-TNF-α vs. Elo + cIgG1; P < 0.01 for 
Elo + Len + anti-TNF-α vs. Elo + Len + cIgG1). f Dose-dependent 
inhibition of myeloma cell growth in the presence of titrated doses 
of TNF-α, but not IFN-γ, on myeloma cells as determined in Alamar 
blue assays on day 4 in vitro. Data are shown from one of two inde-
pendent experiments
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co-cultures increased soluble IL-2 levels (Fig. 5b). The 
IL-2 levels were significantly higher in the elotuzumab plus 
lenalidomide treatment group as compared with either elo-
tuzumab or lenalidomide treatment alone.
To address whether increased soluble IL-2 levels were 
a result of an increase in the frequency of IL-2—secreting 
cells in treated co-cultures, IL-2 ELISPOT assays were 
performed. Both elotuzumab and lenalidomide induced a 
higher frequency of IL-2—secreting cells compared with 
cIgG1-treated cultures. Interestingly, the combination of 
elotuzumab and lenalidomide significantly increased the 
frequency of IL-2—secreting cells compared to co-cul-
tures treated with either elotuzumab or lenalidomide alone 
(Fig. 5c). To determine the cellular source of IL-2, PBMC 
and OPM2 cells were incubated in co-cultures followed by 
positive depletion of specific lymphocyte subsets and sub-
sequent ELISPOT analysis. Depletion of either CD56+ or 
CD3+ cells abolished the IL-2 ELISPOT signal stimulated 
by elotuzumab and lenalidomide (Fig. 5d, e, respectively).
We hypothesized that a CD3+CD56+ lymphocyte pop-
ulation was the source of IL-2. To test this hypothesis, T 
cells (CD3+/CD56−), NK cells (CD3−/CD56+), and lym-
phocytes positive for both CD3 and CD56 from elotu-
zumab plus lenalidomide or cIgG1-treated co-cultures were 
sorted by flow cytometry and used in ELISPOT assays. 
IL-2 ELISPOTs were detected with the CD3+/CD56+ cells 
isolated from elotuzumab plus lenalidomide but not from 
the cIgG1-treated co-cultures (Fig. 5f). Furthermore, IL-2 
Fig. 5  Increased production and consumption of IL-2 stimulated by 
the combination of elotuzumab (Elo) and lenalidomide (Len). NKT 
cells are the source of IL-2 in PBL/myeloma co-cultures. a Deter-
mination of soluble IL-2 levels in co-cultures by Luminex assays 
(n = 17). (Len) plus cIgG1 induced higher levels of IL-2 than cIgG1 
cultures (P < 0.001). IL-2 levels were decreased in (Elo) (P < 0.01 
vs. cIgG1) as well as Elo + Len (P < 0.01 vs. Len + cIgG1) cultures. 
b Addition of blocking antibodies to IL-2Rα (CD25), but not IFN-
γ, increased the accumulation of soluble IL-2 levels in Elo (P < 0.01 
vs. Elo + cIgG1) or Elo + Len (P < 0.01 vs. Elo + Len + cIgG1) 
cultures (n = 6). c Determination of IL-2 ELISPOTs in co-cultures 
(n = 9). A higher frequency of IL-2 ELISPOTs was observed in 
Elo + Len compared with Elo (P < 0.01)- or Len (P < 0.01)-treated 
co-cultures. Significant increase in the frequency of IL-2-secreting 
cells was observed in Elo (P < 0.05) and Len (P < 0.05) compared 
with cIgG1 co-cultures. d Depletion of CD56+ cells significantly 
decreased IL-2 ELISPOTs in Elo + Len co-cultures (P < 0.01 for 
PBMC vs. PBMC-CD56 lymphocytes) (n = 3). e Depletion of CD3+ 
cells significantly decreased IL-2 ELISPOTs in Elo + Len co-cul-
tures (P < 0.01 for PBL vs. PBL-CD3 lymphocytes) (n = 3). f Detec-
tion of IL-2 ELISPOTs with FACS-sorted CD3+CD56+ cells from 
Elo + Len but not from cIgG1-treated co-cultures (n = 1)
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ELISPOTs were not detected with T or NK cells (data not 
shown). These findings demonstrate that elotuzumab plus 
lenalidomide stimulate CD3+/CD56+ lymphocytes to pro-
duce IL-2 and the combination significantly increased both 
the frequency of IL-2-secreting cells and IL-2 levels.
IL-2 contributes to the combinatorial activity 
of elotuzumab and lenalidomide
Based on the evidence above that IL-2 production is 
enhanced but quickly consumed in elotuzumab or elotu-
zumab plus lenalidomide-treated co-cultures as compared 
with lenalidomide alone, we hypothesized that IL-2 pro-
duced by CD3+/CD56+ cells contributed to the elotuzumab 
or elotuzumab plus lenalidomide-mediated NK-dependent 
myeloma cell killing. To assess the role of IL-2 in myeloma 
cell killing, a neutralizing mAb to IL-2 was added to co-
cultures and compared to isotype control. Addition of the 
anti-IL-2 mAb to either elotuzumab or elotuzumab plus 
lenalidomide-treated co-cultures significantly decreased 
myeloma cell killing compared with control (Fig. 6a).
To provide additional support for the hypothesis that 
IL-2 contributes to elotuzumab-mediated NK cell-depend-
ent myeloma cell killing, we examined myeloma cell co-
cultures either with PBL or with purified NK cells in the 
presence of elotuzumab and an exogenous source of IL-2. 
Addition of IL-2 to PBL/OPM2 (Fig. 6b) or NK/OPM2 
(Fig. 6c) co-cultures had no effect on NK cell activation 
or myeloma cell killing. However, addition of IL-2 to elo-
tuzumab in the co-cultures in the presence of either PBL 
(Fig. 6b) or purified NK cells (Fig. 6c) resulted in dose-
dependent myeloma cell killing and NK cell activation 
as determined by CD25 and CD54 upregulation (data not 
shown). These findings demonstrated that IL-2 contributed 
to elotuzumab-mediated NK cell activation and myeloma 
cell killing in the co-cultures.
Discussion
In this study, we investigated mechanisms underlying the 
potential therapeutic benefit of adding elotuzumab to lena-
lidomide. Evidence suggests that elotuzumab alone has 
anti-myeloma activity via NK cell-mediated ADCC activity 
[21, 22, 24, 25], whereas lenalidomide exerts anti-myeloma 
activity through multiple mechanisms, including direct 
cytotoxicity and modulation of immune cell activation 
[4]. Utilizing both in vitro and in vivo models of MM, we 
found that the combination of elotuzumab with lenalido-
mide exerted greater anti-proliferative effects than either 
agent alone. Enhanced inhibition of myeloma cell culture 
growth with the combination of elotuzumab and lenalido-
mide was associated with increased NK cell activation, 
upregulation of adhesion molecules, and stimulation of 
cytokine production.
We showed that elotuzumab treatment of the xeno-
graft models led to recruitment of NK cells to the tumor 
and required intact Fc function. NK cell recruitment was 
not enhanced by treatment with lenalidomide. It is likely 
that enhanced activity in the model was due to increased 
NK cell activation through elotuzumab-mediated ADCC, 
which occurred via recruitment of effector NK cells into 
Fig. 6  IL-2 contributes to the anti-myeloma activity of elotu-
zumab (Elo) in combination with lenalidomide (Len). a Neutrali-
zation of IL-2 with an anti-IL-2 mAb decreases myeloma cell kill-
ing in Elo (P < 0.05 vs. Elo + cIgG1)- or Elo + Len (P < 0.01 vs. 
Elo + Len + cIgG1)-treated PBL/myeloma cell co-cultures on day 
3 (n = 7). Enhancement of myeloma cell killing by graded doses of 
IL-2 (units/mL) in myeloma cell co-cultures with b PBL or c purified 
NK cells at 24 h. Representative data from one of the three donors is 
shown b, c
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SLAMF7/CS1+ tumor xenografts and lenalidomide-medi-
ated direct cytotoxic effects against myeloma cells.
The xenograft results were supported by an in vitro co-
culture model of PBL and myeloma cells. When combined, 
elotuzumab and lenalidomide synergized to produce mye-
loma cell death and NK cell activation across four distinct 
myeloma cell lines. Moreover, functional activation of the 
LFA-1–ICAM-1 pathway was observed in our model, with 
upregulation of ICAM-1 on both NK cells and myeloma 
cells apparent in treated cultures. The interaction of target 
cell-expressed ICAM-1 with its co-receptor LFA-1 on NK 
cells has been shown to play a critical role in adhesion, 
activating immune synapse formation and target cell killing 
[30, 31], and antibody blocking of LFA-1/ICAM-1 inter-
actions impairs NK cell cytotoxicity [32]. When an anti-
CD18 monoclonal antibody that inhibits the interaction of 
LFA-1 and ICAM-1 was administered with elotuzumab or 
elotuzumab in combination with lenalidomide, cell death 
and NK activity were diminished, suggesting the effect was 
dependent on the interaction between elotuzumab Fc and 
NK cell LFA-1.
ADCC mediated by NK cells via Fc–FcR interactions 
has been demonstrated as a key mechanism of action of 
elotuzumab activity. However, SLAMF7 is a known media-
tor of activating signals to NK cells and is also a potentiator 
of NK target cell interactions via homotypic interactions 
[33]. Along with the ability of elotuzumab to engage both 
SLAMF7 and CD16 on NK cells, it has also been shown 
to potentiate SLAMF7–SLAMF7 homotypic interactions 
[26], as it binds a membrane proximal epitope of SLAMF7 
that is not predicted to be involved in homotypic adhesion. 
We demonstrated that in the co-culture model evaluated, 
soluble F(ab′)2 fragments of elotuzumab did not mediate 
significant activity on NK cell activation alone or in com-
bination with lenalidomide, illustrating the importance of 
different model systems and assay conditions for investi-
gating the various mechanisms of action of these agents. 
In the current model system, the CD16-mediated effects of 
elotuzumab may be dominant over SLAMF7-specific con-
tributions of elotuzumab in mediating NK cell-dependent 
killing of MM cells.
TNF-α, IFN-γ, and IL-2 are important inflammatory 
cytokines that influence NK cell activation and may have 
direct cytotoxic effects on myeloma cells. We showed that 
TNF-α, but not IFN-γ, exerted direct anti-myeloma cell 
activity, consistent with previous studies [34, 35]. TNF-α, 
but not IFN-γ, contributed to NK cell activation mediated 
by elotuzumab alone or in combination with lenalidomide. 
The positive effect of lenalidomide on the production of 
IL-2 by CD4+ T cells in the presence or absence of anti-
CD3 stimulation has been previously described [4, 36, 37]. 
IL-2 is also known to play a role in enhancing NK cell 
cytotoxicity and ADCC against cancer cells [38–40].
Using a sensitive ELISPOT analysis, we determined 
that elotuzumab plus lenalidomide induced IL-2 pro-
duction by a CD3+CD56+ population of lymphocytes 
that may include NKT cells, but not conventional T cell 
subsets (CD3+/CD56−) in our co-culture system. The 
immune activation phenotype observed in our studies 
illustrates the complexity of the interaction between elo-
tuzumab and lenalidomide. Aside from the induction of 
IL-2 in the cultures, the upregulation of CD25, a compo-
nent of the high affinity IL-2 receptor complex was noted. 
The functional consequences of blocking the receptor 
were the accumulation of IL-2 in the co-culture superna-
tants and reduced killing of myeloma cells in the cultures. 
Concomitant with the increase in IL-2 pathway compo-
nents, functional activation of the LFA-1-ICAM-1 path-
way was observed, with upregulation of CD54 on both 
NK cells and myeloma cells.
In conclusion, combining elotuzumab and lenalidomide 
provides significant enhancement of NK cell function over 
each agent alone. The enhanced NK cell function is medi-
ated by increased cytokine secretion and upregulation of 
adhesion and activation molecules on myeloma and NK 
cells. Enhanced IL-2 secretion by CD3+/CD56+ cells and 
production of TNF-α led to enhanced killing of myeloma 
cells. While these data suggest that the major effect of 
elotuzumab on NK cell activation is dependent on CD16 
engagement via Fc, future studies will focus on mecha-
nisms of NK activation that are independent of Fc:CD16 
interactions, i.e., direct SLAMF7 engagement.
Combination therapy is the standard of care for the treat-
ment of MM. A better understanding of the potential mech-
anisms of action of novel targeted therapies in combination 
with immunomodulatory and other standard of care agents 
may lead to an improved rational design of clinical trials, 
thereby helping to address the unmet medical need in the 
treatment of MM.
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